MeNZB: A Safe and Highly Immunogenic Tailor-Made Vaccine Against the New Zealand Neisseria Meningitidis Serogroup B Disease Epidemic Strain

Vaccine. 2005 Mar 18;23(17-18):2191-6. doi: 10.1016/j.vaccine.2005.01.063.

Abstract

Clinical studies have been conducted in New Zealand evaluating the safety and immunogenicity of an outer membrane vesicle (OMV) vaccine, MeNZB, developed to control epidemic disease caused by group B meningococci, subtype P1.7b,4. MeNZB, administered in a three-dose regimen, was well tolerated and induced a seroresponse, defined as a four-fold rise (> or =titre 8) in serum bactericidal antibodies against the vaccine strain 4-6 weeks after the third vaccination, in 96% (95% confidence interval (CI): 79-100%) of adults, 76% (95% CI: 72-80%) of children, 75% (95% CI: 69-80%) of toddlers and 74% (95% CI: 67-80%) of infants receiving MeNZB. In conclusion, these findings suggest that MeNZB is safe and is likely to confer protection against systemic group B meningococcal disease caused by the epidemic strain.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Antibodies, Bacterial / blood
  • Bacterial Vaccines / adverse effects
  • Bacterial Vaccines / immunology
  • Bacterial Vaccines / pharmacology*
  • Child
  • Child, Preschool
  • Double-Blind Method
  • Female
  • Humans
  • Infant
  • Male
  • Meningococcal Infections / immunology
  • Meningococcal Infections / prevention & control
  • Middle Aged
  • Neisseria meningitidis, Serogroup B / immunology*
  • New Zealand
  • Safety

Substances

  • Antibodies, Bacterial
  • Bacterial Vaccines